India is the 'diabetes capital of the world', according to a study by the Indian Council of Medical Research that shows the country now has 101 million diabetics, with a further 136 million pre-diabetic individuals, Diabetic cases has increased by 44 per cent in four years from 70 million affected people in 20191.

The average age of onset is 42.5 years. Nearly 1 million Indians die due to diabetes every year. We have a noteworthy presence in Diabetes Therapy Area (TA) through our Diabetology and Metabolic Division. This reinforces our commitment to helping patients manage their diabetes better and improve the quality of their life. We have brands like Glucoryl, Glucoryl M, Glucoryl MV, Valera M, Valera, Voglikem, Dapanorm, Dapanorm M, Euclide-XR, Euclide – M, Formin PG, Gluvilda – M, Gluvilda OD, Olymprix M and Olymprix, in diabetes therapy.

We have exclusivity to market Evogliptin(Valera, Valera M) in India. Alkem’s commitment to fight diabetes has led it to its launch of Dapagliflozin (Dapanorm) and Dapanom M (Dapagliflozin and Metformin fixed-dose combination) in India.

Our aim is to be a key player in Diabetes Therapy by providing affordable solutions to millions of diabetics across India.

Reference : Lancet Diabetes Endocrinol 2023; 11: 474–89

Some of our key brands are: